Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid LeukemiaYoon-Chi Han(Pfizer (United States)), Puja Sapra(Unknown)Clinical Cancer ResearchNovember 4, 202010.1158/1078-0432.ccr-20-2149Cited by 21SaveCiteExport RISWatch citationsRelated PapersSupplementary Methods S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers|Unknown|2025|0